94 related articles for article (PubMed ID: 19377096)
1. 1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) enhances the cytotoxicity of combretastatin A4 independently of mitogen-activated protein kinase kinase.
Quan H; Liu H; Li C; Lou L
J Pharmacol Exp Ther; 2009 Jul; 330(1):326-33. PubMed ID: 19377096
[TBL] [Abstract][Full Text] [Related]
2. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.
Quan H; Xu Y; Lou L
Int J Cancer; 2008 Apr; 122(8):1730-7. PubMed ID: 18074350
[TBL] [Abstract][Full Text] [Related]
3. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
4. Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells.
Lin HL; Chiou SH; Wu CW; Lin WB; Chen LH; Yang YP; Tsai ML; Uen YH; Liou JP; Chi CW
J Pharmacol Exp Ther; 2007 Oct; 323(1):365-73. PubMed ID: 17646428
[TBL] [Abstract][Full Text] [Related]
5. MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth.
Takayama Y; Kokuryo T; Yokoyama Y; Nagino M; Nimura Y; Senga T; Hamaguchi M
Cancer Lett; 2008 Jun; 264(2):241-9. PubMed ID: 18346844
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.
Li Q; Chow AB; Mattingly RR
J Pharmacol Exp Ther; 2010 Mar; 332(3):821-8. PubMed ID: 19952304
[TBL] [Abstract][Full Text] [Related]
7. MEK-inhibitor U0126 in hyperglycaemic focal ischaemic brain injury in the rat.
Farrokhnia N; Ericsson A; Terént A; Lennmyr F
Eur J Clin Invest; 2008 Sep; 38(9):679-85. PubMed ID: 18837745
[TBL] [Abstract][Full Text] [Related]
8. Activation of ERK1/2 in the primary injury site is required to maintain melittin-enhanced wind-up of rat spinal wide-dynamic-range neurons.
Yu YQ; Zhao F; Chen J
Neurosci Lett; 2009 Aug; 459(3):137-41. PubMed ID: 19427362
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the MAP kinase ERK protects from lipopolysaccharide-induced lung injury.
Schuh K; Pahl A
Biochem Pharmacol; 2009 Jun; 77(12):1827-34. PubMed ID: 19428337
[TBL] [Abstract][Full Text] [Related]
10. Potent block of potassium channels by MEK inhibitor U0126 in primary cultures and brain slices.
Wang JZ; Long C; Li KY; Xu HT; Yuan LL; Wu GY
Sci Rep; 2018 Jun; 8(1):8808. PubMed ID: 29892075
[TBL] [Abstract][Full Text] [Related]
11. Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors.
Wityak J; Hobbs FW; Gardner DS; Santella JB; Petraitis JJ; Sun JH; Favata MF; Daulerio AJ; Horiuchi KY; Copeland RA; Scherle PA; Jaffe BD; Trzaskos JM; Magolda RL; Trainor GL; Duncia JV
Bioorg Med Chem Lett; 2004 Mar; 14(6):1483-6. PubMed ID: 15006386
[TBL] [Abstract][Full Text] [Related]
12. Prevention of LLC-PK(1) cell overgrowth in a bioartificial renal tubule device using a MEK inhibitor, U0126.
Inagaki M; Yokoyama TA; Sawada K; Duc VM; Kanai G; Lu J; Kakuta T; Saito A
J Biotechnol; 2007 Oct; 132(1):57-64. PubMed ID: 17884223
[TBL] [Abstract][Full Text] [Related]
13. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
14. The effect of BisGMA on cyclooxygenase-2 expression, PGE2 production and cytotoxicity via reactive oxygen species- and MEK/ERK-dependent and -independent pathways.
Chang MC; Lin LD; Chan CP; Chang HH; Chen LI; Lin HJ; Yeh HW; Tseng WY; Lin PS; Lin CC; Jeng JH
Biomaterials; 2009 Sep; 30(25):4070-7. PubMed ID: 19467701
[TBL] [Abstract][Full Text] [Related]
15. Review of Cytotoxic CA4 Analogues that Do Not Target Microtubules: Implications for CA4 Development.
Tarade D; Pandey S; McNulty J
Mini Rev Med Chem; 2017; 17(16):1507-1514. PubMed ID: 27156516
[TBL] [Abstract][Full Text] [Related]
16. XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro.
Wu R; Ding W; Liu T; Zhu H; Hu Y; Yang B; He Q
Cancer Lett; 2009 Nov; 285(1):13-22. PubMed ID: 19647933
[TBL] [Abstract][Full Text] [Related]
17. The effect of MAPK inhibitors on arsenic trioxide-treated Calu-6 lung cells in relation to cell death, ROS and GSH levels.
Han YH; Moon HJ; You BR; Kim SZ; Kim SH; Park WH
Anticancer Res; 2009 Oct; 29(10):3837-44. PubMed ID: 19846917
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MEK sensitizes paclitaxel-induced apoptosis of human colorectal cancer cells by downregulation of GRP78.
Mhaidat NM; Alali FQ; Matalqah SM; Matalka II; Jaradat SA; Al-Sawalha NA; Thorne RF
Anticancer Drugs; 2009 Aug; 20(7):601-6. PubMed ID: 19521235
[TBL] [Abstract][Full Text] [Related]
20. Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
Kim S; Peshkin L; Mitchison TJ
PLoS One; 2012; 7(7):e40177. PubMed ID: 22848372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
